The USPTO issued Patent No. US12590065B2 to Zevra Therapeutics, Inc. on March 31, 2026, covering compositions comprising levorphanol prodrugs conjugated to oxoacids, polyethylene glycols, and vitamin compounds, along with processes for making and using them. The patent lists CPC classifications including C07D 215/06, C07D 495/04, A61K 31/485, and claims structures under C07K 5/06026 through C07K 5/0812.

This is a routine patent grant that establishes intellectual property protection for the assignee. Pharmaceutical companies developing opioid-analgesic prodrugs or similar compounds should review this patent to assess potential freedom-to-operate implications. No compliance actions or deadlines are required beyond standard IP portfolio monitoring.